By contrast, association between the risk of pancreatic cancer and the use of glucagon-like peptide-1 (GLP-1)-based therapies (including GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes is still under discussion. This evidence concerns the gene GLP1R and pancreatic neoplasm.